tradingkey.logo

Edwards Lifesciences Corp

EW
查看詳細走勢圖
81.610USD
+0.250+0.31%
收盤 01/30, 16:00美東報價延遲15分鐘
47.39B總市值
34.75本益比TTM

Edwards Lifesciences Corp

81.610
+0.250+0.31%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.31%

5天

-2.45%

1月

-4.27%

6月

+2.87%

今年開始到現在

-4.27%

1年

+12.64%

查看詳細走勢圖

TradingKey Edwards Lifesciences Corp股票評分

單位: USD 更新時間: 2026-01-30

操作建議

Edwards Lifesciences Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名10/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為96.46。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Edwards Lifesciences Corp評分

相關信息

行業排名
10 / 205
全市場排名
65 / 4536
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

29°C

過冷
過熱
中性

Edwards Lifesciences Corp亮點

亮點風險
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入5.44B美元
估值合理
公司最新PE估值34.65,處於3年歷史合理位
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉7.71K股

分析師目標

基於 35 分析師
買入
評級
96.154
目標均價
+17.99%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Edwards Lifesciences Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Edwards Lifesciences Corp簡介

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
公司代碼EW
公司Edwards Lifesciences Corp
CEOZovighian (Bernard J)
網址https://www.edwards.com
KeyAI